Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 60 entries
Sorted by: Best Match Show Resources per page
Pentaguanidinium monohydrogendiphosphopentamolybdate(VI) 2.5-hydrate, (CH6N3)5[HP2Mo5O23]·2.5H2O: hydrogen bonding and π-stacking in guanidinium cations.

Acta crystallographica. Section C, Crystal structure communications

Di Tondo P, Pritchard RG.
PMID: 22763679
Acta Crystallogr C. 2012 Jul;68:i50-2. doi: 10.1107/S0108270112024419. Epub 2012 Jun 15.

The asymmetric unit of the title compound consists of two crystallographically independent, but structurally identical, [HP(2)Mo(5)O(23)](5-) anions, ten guanidinium cations and five water molecules. Each singly protonated diphosphopentamolybdate(VI) anion retains the typical geometry of a ring of five edge-sharing...

Cite
Di Tondo P, Pritchard RG. Pentaguanidinium monohydrogendiphosphopentamolybdate(VI) 2.5-hydrate, (CH6N3)5[HP2Mo5O23]·2.5H2O: hydrogen bonding and π-stacking in guanidinium cations. Acta Crystallogr C. 2012;68:i50-2doi: 10.1107/S0108270112024419.
Di Tondo, P., & Pritchard, R. G. (2012). Pentaguanidinium monohydrogendiphosphopentamolybdate(VI) 2.5-hydrate, (CH6N3)5[HP2Mo5O23]·2.5H2O: hydrogen bonding and π-stacking in guanidinium cations. Acta crystallographica. Section C, Crystal structure communications, 68i50-2. https://doi.org/10.1107/S0108270112024419
Di Tondo, Pietro, and Pritchard, Robin Gavin. "Pentaguanidinium monohydrogendiphosphopentamolybdate(VI) 2.5-hydrate, (CH6N3)5[HP2Mo5O23]·2.5H2O: hydrogen bonding and π-stacking in guanidinium cations." Acta crystallographica. Section C, Crystal structure communications vol. 68 (2012): i50-2. doi: https://doi.org/10.1107/S0108270112024419
Di Tondo P, Pritchard RG. Pentaguanidinium monohydrogendiphosphopentamolybdate(VI) 2.5-hydrate, (CH6N3)5[HP2Mo5O23]·2.5H2O: hydrogen bonding and π-stacking in guanidinium cations. Acta Crystallogr C. 2012 Jul;68:i50-2. doi: 10.1107/S0108270112024419. Epub 2012 Jun 15. PMID: 22763679.
Copy Download .nbib Format: NLM
HER-2/neu in bladder carcinoma.

International journal of oncology

Tommasi S, Ditonno P, Sisto M, Paradiso A, Gentile A, Ricco R, Schittulli F, Jacobellis U.
PMID: 21544451
Int J Oncol. 1996 May;8(5):957-61. doi: 10.3892/ijo.8.5.957.

A total of 66 bladder cancer patients were studied to verify possible relationships between HER-2/neu alterations and pathological characteristics, and to define a poor prognosis patient subgroup with respect to time to recurrence, time to progression and survival. Tumor...

Cite
Tommasi S, Ditonno P, Sisto M, et al. HER-2/neu in bladder carcinoma. Int J Oncol. 1996;8(5):957-61doi: 10.3892/ijo.8.5.957.
Tommasi, S., Ditonno, P., Sisto, M., Paradiso, A., Gentile, A., Ricco, R., Schittulli, F., & Jacobellis, U. (1996). HER-2/neu in bladder carcinoma. International journal of oncology, 8(5), 957-61. https://doi.org/10.3892/ijo.8.5.957
Tommasi, S, et al. "HER-2/neu in bladder carcinoma." International journal of oncology vol. 8,5 (1996): 957-61. doi: https://doi.org/10.3892/ijo.8.5.957
Tommasi S, Ditonno P, Sisto M, Paradiso A, Gentile A, Ricco R, Schittulli F, Jacobellis U. HER-2/neu in bladder carcinoma. Int J Oncol. 1996 May;8(5):957-61. doi: 10.3892/ijo.8.5.957. PMID: 21544451.
Copy Download .nbib Format: NLM
Radical penectomy, a compromise for life: results from the PECAD study.

Translational andrology and urology

Ghahhari J, Marchioni M, Spiess PE, Chipollini JJ, Nyirády P, Varga J, Ditonno P, Boccasile S, Primiceri G, De Nunzio C, Tema G, Tubaro A, Veccia A, Antonelli A, Musi G, De Cobelli O, Conti A, Puliatti S, Micali S, Álvarez-Maestro M, Quesada Olarte J, Diogenes E, Lima MVA, Tracey A, Guruli G, Autorino R, Sountoulides P, Sosnowski R, Schips L, Cindolo L.
PMID: 32676414
Transl Androl Urol. 2020 Jun;9(3):1306-1313. doi: 10.21037/tau.2020.04.04.

BACKGROUND: The use of organ sparing strategies to treat penile cancer (PC) is currently supported by evidence that has indicated the safety, efficacy and benefit of this surgery. However, radical penectomy still represents up to 15-20% of primary tumor...

Cite
Ghahhari J, Marchioni M, Spiess PE, et al. Radical penectomy, a compromise for life: results from the PECAD study. Transl Androl Urol. 2020;9(3):1306-1313doi: 10.21037/tau.2020.04.04.
Ghahhari, J., Marchioni, M., Spiess, P. E., Chipollini, J. J., Nyirády, P., Varga, J., Ditonno, P., Boccasile, S., Primiceri, G., De Nunzio, C., Tema, G., Tubaro, A., Veccia, A., Antonelli, A., Musi, G., De Cobelli, O., Conti, A., Puliatti, S., Micali, S., Álvarez-Maestro, M., Quesada Olarte, J., Diogenes, E., Lima, M. V. A., Tracey, A., Guruli, G., Autorino, R., Sountoulides, P., Sosnowski, R., Schips, L., & Cindolo, L. (2020). Radical penectomy, a compromise for life: results from the PECAD study. Translational andrology and urology, 9(3), 1306-1313. https://doi.org/10.21037/tau.2020.04.04
Ghahhari, Jamil, et al. "Radical penectomy, a compromise for life: results from the PECAD study." Translational andrology and urology vol. 9,3 (2020): 1306-1313. doi: https://doi.org/10.21037/tau.2020.04.04
Ghahhari J, Marchioni M, Spiess PE, Chipollini JJ, Nyirády P, Varga J, Ditonno P, Boccasile S, Primiceri G, De Nunzio C, Tema G, Tubaro A, Veccia A, Antonelli A, Musi G, De Cobelli O, Conti A, Puliatti S, Micali S, Álvarez-Maestro M, Quesada Olarte J, Diogenes E, Lima MVA, Tracey A, Guruli G, Autorino R, Sountoulides P, Sosnowski R, Schips L, Cindolo L. Radical penectomy, a compromise for life: results from the PECAD study. Transl Androl Urol. 2020 Jun;9(3):1306-1313. doi: 10.21037/tau.2020.04.04. PMID: 32676414; PMCID: PMC7354339.
Copy Download .nbib Format: NLM
Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis.

Clinical genitourinary cancer

Ferro M, Chiujdea S, Musi G, Lucarelli G, Giudice FD, Hurle R, Damiano R, Cantiello F, Mari A, Minervini A, Busetto GM, Carrieri G, Crocetto F, Barone B, Caputo VF, Cormio L, Ditonno P, Sciarra A, Terracciano D, Cioffi A, Luzzago S, Piccinelli M, Mistretta FA, Vartolomei MD, de Cobelli O.
PMID: 35033480
Clin Genitourin Cancer. 2021 Dec 10; doi: 10.1016/j.clgc.2021.12.005. Epub 2021 Dec 10.

INTRODUCTION: The aim of this multicenter study was to investigate the role of age (cut-off 70 years) at diagnosis in predicting oncologic behavior of pure carcinoma in situ of the bladder.MATERIAL AND METHODS: Inclusion criteria were: patients with pure...

Cite
Ferro M, Chiujdea S, Musi G, et al. Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. Clin Genitourin Cancer. 2021;doi: 10.1016/j.clgc.2021.12.005.
Ferro, M., Chiujdea, S., Musi, G., Lucarelli, G., Giudice, F. D., Hurle, R., Damiano, R., Cantiello, F., Mari, A., Minervini, A., Busetto, G. M., Carrieri, G., Crocetto, F., Barone, B., Caputo, V. F., Cormio, L., Ditonno, P., Sciarra, A., Terracciano, D., Cioffi, A., Luzzago, S., Piccinelli, M., Mistretta, F. A., Vartolomei, M. D., & de Cobelli, O. (2021). Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. Clinical genitourinary cancer, . https://doi.org/10.1016/j.clgc.2021.12.005
Ferro, Matteo, et al. "Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis." Clinical genitourinary cancer vol. (2021). doi: https://doi.org/10.1016/j.clgc.2021.12.005
Ferro M, Chiujdea S, Musi G, Lucarelli G, Giudice FD, Hurle R, Damiano R, Cantiello F, Mari A, Minervini A, Busetto GM, Carrieri G, Crocetto F, Barone B, Caputo VF, Cormio L, Ditonno P, Sciarra A, Terracciano D, Cioffi A, Luzzago S, Piccinelli M, Mistretta FA, Vartolomei MD, de Cobelli O. Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. Clin Genitourin Cancer. 2021 Dec 10; doi: 10.1016/j.clgc.2021.12.005. Epub 2021 Dec 10. PMID: 35033480.
Copy Download .nbib Format: NLM
Robot-assisted Radical Nephrectomy: A Systematic Review and Meta-analysis of Comparative Studies.

European urology

Crocerossa F, Carbonara U, Cantiello F, Marchioni M, Ditonno P, Mir MC, Porpiglia F, Derweesh I, Hampton LJ, Damiano R, Autorino R.
PMID: 33218826
Eur Urol. 2021 Oct;80(4):428-439. doi: 10.1016/j.eururo.2020.10.034. Epub 2020 Nov 18.

CONTEXT: Radical nephrectomy (RN) is the gold standard treatment for large and locally advanced renal tumors. Although robot-assisted radical nephrectomy (RRN) is being increasingly adopted, it remains unclear whether it offers benefits over standard laparoscopic radical nephrectomy (LRN) or...

Cite
Crocerossa F, Carbonara U, Cantiello F, et al. Robot-assisted Radical Nephrectomy: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2020;80(4):428-439doi: 10.1016/j.eururo.2020.10.034.
Crocerossa, F., Carbonara, U., Cantiello, F., Marchioni, M., Ditonno, P., Mir, M. C., Porpiglia, F., Derweesh, I., Hampton, L. J., Damiano, R., & Autorino, R. (2021). Robot-assisted Radical Nephrectomy: A Systematic Review and Meta-analysis of Comparative Studies. European urology, 80(4), 428-439. https://doi.org/10.1016/j.eururo.2020.10.034
Crocerossa, Fabio, et al. "Robot-assisted Radical Nephrectomy: A Systematic Review and Meta-analysis of Comparative Studies." European urology vol. 80,4 (2021): 428-439. doi: https://doi.org/10.1016/j.eururo.2020.10.034
Crocerossa F, Carbonara U, Cantiello F, Marchioni M, Ditonno P, Mir MC, Porpiglia F, Derweesh I, Hampton LJ, Damiano R, Autorino R. Robot-assisted Radical Nephrectomy: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2021 Oct;80(4):428-439. doi: 10.1016/j.eururo.2020.10.034. Epub 2020 Nov 18. PMID: 33218826.
Copy Download .nbib Format: NLM
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma.

Journal of clinical medicine

Di Lernia G, Leone P, Solimando AG, Buonavoglia A, Saltarella I, Ria R, Ditonno P, Silvestris N, Crudele L, Vacca A, Racanelli V.
PMID: 32085480
J Clin Med. 2020 Feb 18;9(2). doi: 10.3390/jcm9020552.

Although the introduction of bortezomib as a therapeutic strategy has improved the overall survival of multiple myeloma (MM) patients, 15-20% of high-risk patients do not respond to bortezomib over time or become resistant to treatment. Therefore, the development of...

Cite
Di Lernia G, Leone P, Solimando AG, et al. Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. J Clin Med. 2020;9(2)doi: 10.3390/jcm9020552.
Di Lernia, G., Leone, P., Solimando, A. G., Buonavoglia, A., Saltarella, I., Ria, R., Ditonno, P., Silvestris, N., Crudele, L., Vacca, A., & Racanelli, V. (2020). Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. Journal of clinical medicine, 9(2), . https://doi.org/10.3390/jcm9020552
Di Lernia, Giuseppe, et al. "Bortezomib Treatment Modulates Autophagy in Multiple Myeloma." Journal of clinical medicine vol. 9,2 (2020). doi: https://doi.org/10.3390/jcm9020552
Di Lernia G, Leone P, Solimando AG, Buonavoglia A, Saltarella I, Ria R, Ditonno P, Silvestris N, Crudele L, Vacca A, Racanelli V. Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. J Clin Med. 2020 Feb 18;9(2). doi: 10.3390/jcm9020552. PMID: 32085480; PMCID: PMC7073518.
Copy Download .nbib Format: NLM
Zimmermann-Laband-1 Syndrome: Clinical, Histological, and Proteomic Findings of a 3-Year-Old Patient with Hereditary Gingival Fibromatosis.

Biomedicines

Guglielmi F, Staderini E, Iavarone F, Di Tonno L, Gallenzi P.
PMID: 31261938
Biomedicines. 2019 Jun 29;7(3). doi: 10.3390/biomedicines7030048.

BACKGROUND: Zimmermann-Laband-1 syndrome (ZLS-1; OMIM# 135500) is a rare genetic disorder whose oral pathognomonic sign is the development of progressive, diffuse, and severe gingival hypertrophy. Most children with abnormally gingival hyperplasia may also present multiple unerupted teeth and skeletal...

Cite
Guglielmi F, Staderini E, Iavarone F, et al. Zimmermann-Laband-1 Syndrome: Clinical, Histological, and Proteomic Findings of a 3-Year-Old Patient with Hereditary Gingival Fibromatosis. Biomedicines. 2019;7(3)doi: 10.3390/biomedicines7030048.
Guglielmi, F., Staderini, E., Iavarone, F., Di Tonno, L., & Gallenzi, P. (2019). Zimmermann-Laband-1 Syndrome: Clinical, Histological, and Proteomic Findings of a 3-Year-Old Patient with Hereditary Gingival Fibromatosis. Biomedicines, 7(3), . https://doi.org/10.3390/biomedicines7030048
Guglielmi, Federica, et al. "Zimmermann-Laband-1 Syndrome: Clinical, Histological, and Proteomic Findings of a 3-Year-Old Patient with Hereditary Gingival Fibromatosis." Biomedicines vol. 7,3 (2019). doi: https://doi.org/10.3390/biomedicines7030048
Guglielmi F, Staderini E, Iavarone F, Di Tonno L, Gallenzi P. Zimmermann-Laband-1 Syndrome: Clinical, Histological, and Proteomic Findings of a 3-Year-Old Patient with Hereditary Gingival Fibromatosis. Biomedicines. 2019 Jun 29;7(3). doi: 10.3390/biomedicines7030048. PMID: 31261938; PMCID: PMC6783959.
Copy Download .nbib Format: NLM
Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics.

Diseases (Basel, Switzerland)

Ragone R, Sallustio F, Piccinonna S, Rutigliano M, Vanessa G, Palazzo S, Lucarelli G, Ditonno P, Battaglia M, Fanizzi FP, Schena FP.
PMID: 28933387
Diseases. 2016 Jan 22;4(1). doi: 10.3390/diseases4010007.

Renal cell carcinoma (RCC) is a heterogeneous cancer often showing late symptoms. Until now, some candidate protein markers have been proposed for its diagnosis. Metabolomics approaches have been applied, predominantly using Mass Spectrometry (MS), while Nuclear Magnetic Resonance (NMR)-based...

Cite
Ragone R, Sallustio F, Piccinonna S, et al. Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics. Diseases. 2016;4(1)doi: 10.3390/diseases4010007.
Ragone, R., Sallustio, F., Piccinonna, S., Rutigliano, M., Vanessa, G., Palazzo, S., Lucarelli, G., Ditonno, P., Battaglia, M., Fanizzi, F. P., & Schena, F. P. (2016). Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics. Diseases (Basel, Switzerland), 4(1), . https://doi.org/10.3390/diseases4010007
Ragone, Rosa, et al. "Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics." Diseases (Basel, Switzerland) vol. 4,1 (2016). doi: https://doi.org/10.3390/diseases4010007
Ragone R, Sallustio F, Piccinonna S, Rutigliano M, Vanessa G, Palazzo S, Lucarelli G, Ditonno P, Battaglia M, Fanizzi FP, Schena FP. Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics. Diseases. 2016 Jan 22;4(1). doi: 10.3390/diseases4010007. PMID: 28933387; PMCID: PMC5456302.
Copy Download .nbib Format: NLM
Sex chromosome complement contributes to sex differences in coxsackievirus B3 but not influenza A virus pathogenesis.

Biology of sex differences

Robinson DP, Huber SA, Moussawi M, Roberts B, Teuscher C, Watkins R, Arnold AP, Klein SL.
PMID: 21806829
Biol Sex Differ. 2011 Aug 01;2:8. doi: 10.1186/2042-6410-2-8.

BACKGROUND: Both coxsackievirus B3 (CVB3) and influenza A virus (IAV; H1N1) produce sexually dimorphic infections in C57BL/6 mice. Gonadal steroids can modulate sex differences in response to both viruses. Here, the effect of sex chromosomal complement in response to...

Cite
Robinson DP, Huber SA, Moussawi M, et al. Sex chromosome complement contributes to sex differences in coxsackievirus B3 but not influenza A virus pathogenesis. Biol Sex Differ. 2011;2:8doi: 10.1186/2042-6410-2-8.
Robinson, D. P., Huber, S. A., Moussawi, M., Roberts, B., Teuscher, C., Watkins, R., Arnold, A. P., & Klein, S. L. (2011). Sex chromosome complement contributes to sex differences in coxsackievirus B3 but not influenza A virus pathogenesis. Biology of sex differences, 28. https://doi.org/10.1186/2042-6410-2-8
Robinson, Dionne P, et al. "Sex chromosome complement contributes to sex differences in coxsackievirus B3 but not influenza A virus pathogenesis." Biology of sex differences vol. 2 (2011): 8. doi: https://doi.org/10.1186/2042-6410-2-8
Robinson DP, Huber SA, Moussawi M, Roberts B, Teuscher C, Watkins R, Arnold AP, Klein SL. Sex chromosome complement contributes to sex differences in coxsackievirus B3 but not influenza A virus pathogenesis. Biol Sex Differ. 2011 Aug 01;2:8. doi: 10.1186/2042-6410-2-8. PMID: 21806829; PMCID: PMC3162877.
Copy Download .nbib Format: NLM
Subcutaneous recombinant interleukin-2 plus alpha interferon and vinblastine in metastatic renal cell carcinoma.

International journal of oncology

Guida M, Latorre A, Selvaggi F, Ditonno P, Lorusso V, Mastria A, Delena M.
PMID: 21533401
Int J Oncol. 1997 Mar;10(3):487-91. doi: 10.3892/ijo.10.3.487.

The management of metastatic renal cell carcinoma (RCC) constitutes a therapeutic challenge and no standard therapy has yet been established. This phase II study aimed to verify the efficacy and tolerability of subcutaneous low dose recombinant interleukin-2 (IL-2) plus...

Cite
Guida M, Latorre A, Selvaggi F, et al. Subcutaneous recombinant interleukin-2 plus alpha interferon and vinblastine in metastatic renal cell carcinoma. Int J Oncol. 1997;10(3):487-91doi: 10.3892/ijo.10.3.487.
Guida, M., Latorre, A., Selvaggi, F., Ditonno, P., Lorusso, V., Mastria, A., & Delena, M. (1997). Subcutaneous recombinant interleukin-2 plus alpha interferon and vinblastine in metastatic renal cell carcinoma. International journal of oncology, 10(3), 487-91. https://doi.org/10.3892/ijo.10.3.487
Guida, M, et al. "Subcutaneous recombinant interleukin-2 plus alpha interferon and vinblastine in metastatic renal cell carcinoma." International journal of oncology vol. 10,3 (1997): 487-91. doi: https://doi.org/10.3892/ijo.10.3.487
Guida M, Latorre A, Selvaggi F, Ditonno P, Lorusso V, Mastria A, Delena M. Subcutaneous recombinant interleukin-2 plus alpha interferon and vinblastine in metastatic renal cell carcinoma. Int J Oncol. 1997 Mar;10(3):487-91. doi: 10.3892/ijo.10.3.487. PMID: 21533401.
Copy Download .nbib Format: NLM
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis.

Frontiers in oncology

Ferro M, de Cobelli O, Musi G, Lucarelli G, Terracciano D, Pacella D, Muto T, Porreca A, Busetto GM, Del Giudice F, Soria F, Gontero P, Cantiello F, Damiano R, Crocerossa F, Farhan ARA, Autorino R, Vartolomei MD, Muto M, Marchioni M, Mari A, Scafuri L, Minervini A, Longo N, Chiancone F, Perdona S, De Placido P, Verde A, Catellani M, Luzzago S, Mistretta FA, Ditonno P, Caputo VF, Battaglia M, Zamboni S, Antonelli A, Greco F, Russo GI, Hurle R, Crisan N, Manfredi M, Porpiglia F, Di Lorenzo G, Crocetto F, Buonerba C.
PMID: 34046347
Front Oncol. 2021 May 11;11:651745. doi: 10.3389/fonc.2021.651745. eCollection 2021.

BACKGROUND: Three or four cycles of cisplatin-based chemotherapy is the standard neoadjuvant treatment prior to cystectomy in patients with muscle-invasive bladder cancer. Although NCCN guidelines recommend 4 cycles of cisplatin-gemcitabine, three cycles are also commonly administered in clinical practice....

Cite
Ferro M, de Cobelli O, Musi G, et al. Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. Front Oncol. 2021;11:651745doi: 10.3389/fonc.2021.651745.
Ferro, M., de Cobelli, O., Musi, G., Lucarelli, G., Terracciano, D., Pacella, D., Muto, T., Porreca, A., Busetto, G. M., Del Giudice, F., Soria, F., Gontero, P., Cantiello, F., Damiano, R., Crocerossa, F., Farhan, A. R. A., Autorino, R., Vartolomei, M. D., Muto, M., Marchioni, M., Mari, A., Scafuri, L., Minervini, A., Longo, N., Chiancone, F., Perdona, S., De Placido, P., Verde, A., Catellani, M., Luzzago, S., Mistretta, F. A., Ditonno, P., Caputo, V. F., Battaglia, M., Zamboni, S., Antonelli, A., Greco, F., Russo, G. I., Hurle, R., Crisan, N., Manfredi, M., Porpiglia, F., Di Lorenzo, G., Crocetto, F., & Buonerba, C. (2021). Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. Frontiers in oncology, 11651745. https://doi.org/10.3389/fonc.2021.651745
Ferro, Matteo, et al. "Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis." Frontiers in oncology vol. 11 (2021): 651745. doi: https://doi.org/10.3389/fonc.2021.651745
Ferro M, de Cobelli O, Musi G, Lucarelli G, Terracciano D, Pacella D, Muto T, Porreca A, Busetto GM, Del Giudice F, Soria F, Gontero P, Cantiello F, Damiano R, Crocerossa F, Farhan ARA, Autorino R, Vartolomei MD, Muto M, Marchioni M, Mari A, Scafuri L, Minervini A, Longo N, Chiancone F, Perdona S, De Placido P, Verde A, Catellani M, Luzzago S, Mistretta FA, Ditonno P, Caputo VF, Battaglia M, Zamboni S, Antonelli A, Greco F, Russo GI, Hurle R, Crisan N, Manfredi M, Porpiglia F, Di Lorenzo G, Crocetto F, Buonerba C. Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. Front Oncol. 2021 May 11;11:651745. doi: 10.3389/fonc.2021.651745. eCollection 2021. PMID: 34046347; PMCID: PMC8144638.
Copy Download .nbib Format: NLM
Robotic-assisted Partial Nephrectomy for "Very Small" (<2 cm) Renal Mass: Results of a Multicenter Contemporary Cohort.

European urology focus

Carbonara U, Simone G, Minervini A, Sundaram CP, Larcher A, Lee J, Checcucci E, Fiori C, Patel D, Meagher M, Crocerossa F, Veccia A, Hampton LJ, Ditonno P, Battaglia M, Brassetti A, Bove A, Mari A, Campi R, Carini M, Sulek J, Montorsi F, Capitanio U, Eun D, Porpiglia F, Derweesh I, Autorino R.
PMID: 33153954
Eur Urol Focus. 2021 Sep;7(5):1115-1120. doi: 10.1016/j.euf.2020.10.001. Epub 2020 Nov 03.

BACKGROUND: Patient with "very small" (

Cite
Carbonara U, Simone G, Minervini A, et al. Robotic-assisted Partial Nephrectomy for "Very Small" (<2 cm) Renal Mass: Results of a Multicenter Contemporary Cohort. Eur Urol Focus. 2020;7(5):1115-1120doi: 10.1016/j.euf.2020.10.001.
Carbonara, U., Simone, G., Minervini, A., Sundaram, C. P., Larcher, A., Lee, J., Checcucci, E., Fiori, C., Patel, D., Meagher, M., Crocerossa, F., Veccia, A., Hampton, L. J., Ditonno, P., Battaglia, M., Brassetti, A., Bove, A., Mari, A., Campi, R., Carini, M., Sulek, J., Montorsi, F., Capitanio, U., Eun, D., Porpiglia, F., Derweesh, I., & Autorino, R. (2021). Robotic-assisted Partial Nephrectomy for "Very Small" (<2 cm) Renal Mass: Results of a Multicenter Contemporary Cohort. European urology focus, 7(5), 1115-1120. https://doi.org/10.1016/j.euf.2020.10.001
Carbonara, Umberto, et al. "Robotic-assisted Partial Nephrectomy for "Very Small" (<2 cm) Renal Mass: Results of a Multicenter Contemporary Cohort." European urology focus vol. 7,5 (2021): 1115-1120. doi: https://doi.org/10.1016/j.euf.2020.10.001
Carbonara U, Simone G, Minervini A, Sundaram CP, Larcher A, Lee J, Checcucci E, Fiori C, Patel D, Meagher M, Crocerossa F, Veccia A, Hampton LJ, Ditonno P, Battaglia M, Brassetti A, Bove A, Mari A, Campi R, Carini M, Sulek J, Montorsi F, Capitanio U, Eun D, Porpiglia F, Derweesh I, Autorino R. Robotic-assisted Partial Nephrectomy for "Very Small" (<2 cm) Renal Mass: Results of a Multicenter Contemporary Cohort. Eur Urol Focus. 2021 Sep;7(5):1115-1120. doi: 10.1016/j.euf.2020.10.001. Epub 2020 Nov 03. PMID: 33153954.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 60 entries